Cancer is a group of diseases involving abnormal growth of cells with the potential to spread to other parts of the body. There are various types of cancers affecting different parts of the body. Cancer which develops in the cervix is called cervical cancer. Two major types of cervical cancers diagnosed in women include adenocarcinoma and squamous cell carcinoma. Almost all types of cervical cancer are caused by human papiloma virus (HPV). Cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 3,00,000 deaths annually. Diagnosis of cervical cancer is done by Pap Smear Tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC). Cervical cancer is a sexually transmitted disease that can be prevented by early detection and vaccination.
Cervical cancer diagnostics market is driven majorly by increasing the percentage of HPV-infected people across the globe. HPV is an extremely common virus. According to the Centers for Disease Control and Prevention (CDC), six million people in the United States acquire HPV each year. At least 20 million already have it, and more than half of all sexually active adults are expected to be infected during their lifetime. Furthermore, rising awareness, literacy rate, government initiatives, government funding and various screening methods are expected to increase the growth of the market over the years. Moreover, many lifestyle-related factors, such as having multiple sex partners, smoking, obesity, unsafe sex and inherited HPV-positive patients, are estimated to drive the cervical diagnostics market in the near future. However, prevention of HPV by vaccination is major restraining factor in the growth of cervical cancer diagnostics market. In addition to this, the uncertain returning policy serves to be a major challenge impacting the growth of cervical cancer diagnostics market.
For Sample Report CLICK HERE
The report covers forecast and analysis of the cervical cancer diagnostics market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cervical cancer diagnostics market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides detailed segmentation of the cervical cancer diagnostics market based on application and region. The regional market segment held the largest market share in 2015.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America dominated the global cervical cancer diagnostic market in 2015 on account of the rising incidence of HPV infection, rising number of women smokers, and growing aged population. North America was followed by Europe in 2015. The market is expected to witness the growth in the Asia-Pacific region in the coming years due to the rising HPV infection in the population, government initiative and availability of advance health care infrastructure.
Request Sample copy of this Report @ https://www.zionmarketresearch.com/sample/cervical-cancer-diagnostics-market
Some of the key players contributing to the cervical cancer diagnostics market are Abbott Laboratories, Qiagen N.V., Hologic Inc., Roche Diagnostics, Quest Diagnostics, Becton, Dickinson and Company